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Abstract
Background
Typhoid persists as a major cause of global morbidity. While several licensed vaccines to
prevent typhoid are available, they are of only moderate efficacy and unsuitable for use in
children less than two years of age. Development of new efficacious vaccines is compli-
cated by the human host-restriction of Salmonella enterica serovar Typhi (S. Typhi) and
lack of clear correlates of protection. In this study, we aimed to evaluate the protective effi-
cacy of a single dose of the oral vaccine candidate, M01ZH09, in susceptible volunteers by
direct typhoid challenge.
Methods and Findings
We performed a randomised, double-blind, placebo-controlled trial in healthy adult partici-
pants at a single centre in Oxford (UK). Participants were allocated to receive one dose of
double-blinded M01ZH09 or placebo or 3-doses of open-label Ty21a. Twenty-eight days
after vaccination, participants were challenged with 104CFU S. Typhi Quailes strain. The
efficacy of M01ZH09 compared with placebo (primary outcome) was assessed as the per-
centage of participants reaching pre-defined endpoints constituting typhoid diagnosis (fever
and/or bacteraemia) during the 14 days after challenge. Ninety-nine participants were ran-
domised to receive M01ZH09 (n = 33), placebo (n = 33) or 3-doses of Ty21a (n = 33). After
challenge, typhoid was diagnosed in 18/31 (58.1% [95% CI 39.1 to 75.5]) M01ZH09, 20/30
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(66.7% [47.2 to 87.2]) placebo, and 13/30 (43.3% [25.5 to 62.6]) Ty21a vaccine recipients.
Vaccine efficacy (VE) for one dose of M01ZH09 was 13% [95% CI -29 to 41] and 35% [-5 to
60] for 3-doses of Ty21a. Retrospective multivariable analyses demonstrated that pre-exist-
ing anti-Vi antibody significantly reduced susceptibility to infection after challenge; a 1 log
increase in anti-Vi IgG resulting in a 71% decrease in the hazard ratio of typhoid diagnosis
([95% CI 30 to 88%], p = 0.006) during the 14 day challenge period. Limitations to the study
included the requirement to limit the challenge period prior to treatment to 2 weeks, the
intensity of the study procedures and the high challenge dose used resulting in a stringent
model.
Conclusions
Despite successfully demonstrating the use of a human challenge study to directly evaluate
vaccine efficacy, a single-dose M01ZH09 failed to demonstrate significant protection after
challenge with virulent Salmonella Typhi in this model. Anti-Vi antibody detected prior to
vaccination played a major role in outcome after challenge.
Trial registration
ClinicalTrials.gov (NCT01405521) and EudraCT (number 2011-000381-35).
Author Summary
Typhoid fever is a common cause of febrile illness in tropical countries. Although currently
available typhoid vaccines are moderately effective, they are not suitable for use in young
children. Development of new vaccines is complicated as Salmonella Typhi, the causative
bacteria, only infect humans. In this study, we used a recently developed human typhoid
challenge model to directly assess the efficacy of a new oral vaccine candidate, M01ZH09,
compared to placebo. A parallel group of participants were given 3-doses of licensed oral
Ty21a vaccine as a positive comparator. We found that a single dose of M01ZH09 was not
effective in preventing typhoid infection in our model, although significant effects were seen
in delaying onset of infection and reducing bacterial numbers. Ty21a also failed to signifi-
cantly protect against infection suggesting our model was particularly stringent. We discov-
ered that anti-Vi antibodies, present in some individuals prior to vaccination, contributed
significantly to preventing infection in some individuals, and when this effect was taken into
account, M01ZH09 halved the risk of developing typhoid after being challenged. These
results demonstrate the utility of human challenge models in assessing the efficacy of new
typhoid vaccine candidates, and suggest that further development of M01ZH09 dosing or
delivery strategies may produce better results. These results also support further develop-
ment of Vi-based vaccines as a potentially preventive intervention.
Introduction
Typhoid fever, caused by Salmonella enterica serovar Typhi (S. Typhi), continues to be a major
cause of global morbidity and poverty, particularly in areas without basic sanitation and limited
access to clean water, and among non-immune travellers to those settings [1–3]. Despite caus-
ing an estimated 22 million new cases each year, vaccination to prevent typhoid infection has
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been little implemented [4, 5]. Licensed vaccines have demonstrated moderate efficacy in pre-
venting infection in older children and adults, but are not suitable for use in young children
and infants less than 2 years of age [6, 7]. Development of new efficacious vaccines is compli-
cated by the human host-restriction of S. Typhi, the lack of clear correlates of protection, the
scale required to run field trials of efficacy and uncertainty about estimation of vaccine impact
due to suboptimal diagnostics. A human challenge model can be used to overcome some of
these difficulties and can provide some direct estimation of efficacy in vaccine recipients who
are deliberately exposed to the pathogen in a controlled setting [8].
M01ZH09 is a live attenuated oral vaccine constructed from the parent Ty2 strain by
defined, independently attenuated deletion of the ssaV and aroC genes [9]. A single dose of
M01ZH09 vaccine has proven to be well-tolerated and highly immunogenic in six previous
phase I and IIa studies [10–13]. In particular, high levels of anti-lipopolysaccharide (LPS) anti-
bodies were generated in response to vaccination in studies conducted in both low- and high-
endemicity areas and in diverse age groups [10–13]. Evidence to support anti-LPS response as
a useful protective parameter is limited, and mostly derived from observations made in
endemic settings [14, 15]. Evaluation of typhoid vaccines in previous human challenge studies
has been instrumental in their development, notably for Ty21a, which is also a live attenuated
vaccine derived from Ty2 but does not constitutively express the Vi (Virulence) capsular poly-
saccharide and contains multiple additional genetic attenuations [16–18].
The aim of this study was to assess whether a single dose of oral M01ZH09 could protect
healthy adult volunteers against developing typhoid infection in a challenge model, 28 days
after vaccination. In our recently developed challenge model, ingestion of 104 CFU virulent S.
Typhi Quailes strain bacteria resulted in a 65% attack rate in unvaccinated adult volunteers
[19]. Suitability of the model for vaccine efficacy (VE) evaluation was assessed in parallel by
using the 3-dose schedule of oral Ty21a vaccine as an open-label comparator group.
Methods
Study design
A randomised, double-blind, placebo-controlled trial was performed at the Oxford Vaccine
Group in the Centre for Clinical Vaccinology and Tropical Medicine (Churchill Hospital,
Oxford, UK) to assess the protective efficacy of a single dose of M01ZH09 compared to placebo
against S. Typhi challenge 28 days after vaccination.
This phase 2b trial was sponsored and monitored by the Oxford University Clinical Trials
and Research Governance Department, approved by NRES South Central–Oxford A (11/SC/
0302) and conducted in accordance with the principles of the International Conference of Har-
monisation, Good Clinical Practice guidelines. After study initiation (November 2011), an
independent Data and Safety Monitoring Committee reviewed clinical and laboratory data
relating to patient safety (months 1, 5 and 8) and interim unblinded analyses of VE (months 5
and 8). No changes to the study protocol or participant eligibility were recommended.
Participants
Potential participants from the community were approached using a variety of media including
postal leaflets, e-mails, advertising posters and local newspaper and football programme adver-
tising. Interested individuals were then invited to contact the study centre for further discus-
sion and to receive written study information prior to invitation for eligibility assessment and
enrolment. Eligible participants were healthy men and non-pregnant women, aged 18 to 60
years with no previous history of typhoid vaccination, infection or likely exposure to S. Typhi.
All eligible volunteers were provided with detailed pre-study counselling and provided written
M01ZH09 and Typhoid Fever
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informed consent. Following consent, participants were thoroughly evaluated for health prob-
lems by history, physical examination, blood screening and ultrasound examination of the gall
bladder. A full description of the inclusion/exclusion criteria can be found in the study protocol
(S1 Protocol).
Randomisation and masking
We randomised participants to a double blind or open-label (Ty21a) arm in a 2:1 ratio, with
further randomisation of the double blind arm to M01ZH09 or placebo (1:1 ratio). Randomisa-
tion lists were computer generated by permuted block randomisation with variable block sizes.
Blinding was effected through identical packaging and allocation concealment by sequentially
numbered sealed opaque envelopes. An independent study statistician (LMY) generated the
randomisation sequence and provided sealed envelopes containing allocation codes. Partici-
pants and study staff remained unaware of group allocation until four weeks after the comple-
tion of the challenge phase, at which point specific, unblinded study team members revealed
vaccine assignment to the participant only. These study team members took no part in per-
forming the laboratory assays or data analysis.
Procedures
A single dose of the study vaccine, M01ZH09 (Emergent BioSolutions, Wokingham, UK), con-
taining 1x1010 CFU of live attenuated S. Typhi (Ty2 ΔaroC ΔssaV) ZH09 strain was re-sus-
pended in 20mL NaHCO3[aq] solution prior to ingestion. Placebo, containing excipients only
(M9S basal medium plus 10%(w/w) sucrose), was re-suspended in an identical fashion. Partici-
pants were fasted for one hour before and after vaccine ingestion. Participants in the open-
label arm ingested three capsules of enteric-coated Ty21a vaccine (Crucell UK Ltd, High Wyc-
ombe, UK), containing not less than 2x109 CFU on alternate days, in accordance with manu-
facturer’s instructions [20].
Assessment of immune responses to vaccination
Antibody secreting cell (ASC) responses to LPS, flagellin and Vi were measured at baseline
and 7 days after vaccination by ELISpot assay. Briefly, peripheral blood mononuclear cells
(PBMC) separated from venous blood, were dispensed in concentrations of 2.5 or 5.0x106
cells/mL to nitrocellulose plates pre-coated with lipopolysaccharide (S. Typhosa LPS,
L2387; Sigma-Aldrich, Dorset, UK), Vi (Sanofi Pasteur, Maidenhead, UK), flagellin (pre-
pared by isolation from S. Typhi Quailes strain and purification at the University of Mary-
land School of Medicine) or buffer only (negative control). After overnight incubation and
wash steps, alkaline-phosphatase goat anti-human IgG, IgM and IgA antibodies were
added. After further incubation spots were developed with alkaline phosphatase substrates.
Spots were manually counted by two independent observers and expressed as spots/1x106
PBMC.
Antibody responses were measured 28 days after vaccination (immediately prior to S. Typhi
challenge) and compared with those collected at baseline (pre-vaccination). Specific immuno-
globulin G (IgG), IgA and IgM isotype responses to LPS and flagellin were measured in serum
as previously described [19]. In addition, immunoglobulin G (IgG) responses to Vi were mea-
sured using a commercial ELISA kit (VaccZyme, The Binding Site Ltd, Birmingham, UK)
according to the manufacturer’s instructions.
M01ZH09 and Typhoid Fever
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S. Typhi challenge
Four weeks after vaccination participants were challenged with S. Typhi, Quailes strain, as
described previously [19]; day 0 was defined as the day of challenge. A target challenge dose of
1-5x104 CFU was used to achieve a 65% attack rate in participants allocated to placebo (S1
Fig). After fasting for 90 minutes participants ingested 12g/120mL NaHCO3 [aq] followed
two minutes later by the challenge inoculum suspended in 053g/30mL NaHCO3 [aq]. Follow-
ing challenge, participants were observed for a further 90 minutes prior to leaving the clinic.
Outcomes
Participants were reviewed at least daily at the study site for 14 days, except for days 2 and 4
after challenge when they were telephoned twice instead, or if additional visits were required.
Assessments performed included clinical evaluation and microbiological assay of blood and
stool samples as described below and in the study protocol (S1 Protocol).
The primary study objective was to assess the efficacy of M01ZH09 or Ty21a vaccines com-
pared with placebo in preventing infection during the 2-weeks after S. Typhi challenge.
Typhoid diagnosis (TD) was defined as either, a) oral temperature38°C sustained for12
hours or more after day 5 of challenge, b) a blood culture positive for S. Typhi taken after day 7
of challenge, or c) a blood culture positive for S. Typhi collected after day 5 plus objective symp-
toms or signs (including fever) of typhoid infection.
Severe typhoid fever was defined as a case fulfilling the criteria for TD with the addition of
one or more of the following features: oral temperature recorded40°C, systolic blood pres-
sure85mmHg, significant lethargy or confusion, a GI bleeding event or suspected/confirmed
perforation, or any Grade 4 (‘life threatening’) laboratory abnormality.
Typhoid diagnosis procedures
Participants fulfilling the criteria for typhoid diagnosis were assessed by a physician and initi-
ated on antibiotic treatment and other medication required for symptom control. Antibiotic
treatment given either at TD or at day 14 (in those not developing features of infection) was
ciprofloxacin 500mg twice daily for 14 days (first-line), or azithromycin 500mg once daily for 7
days (second-line). Following diagnosis, participants were reassessed at 6, 12, 24, 48, 72 and 96
hours, to ensure resolution of clinical symptoms and bacteriological cure. In the event that a
first positive blood culture result was received beyond Day 14 after challenge (and thus after
commencement of antibiotic treatment), a TD assessment was made and further visits were
arranged as determined by the study investigator. Compliance with antibiotic treatment was
determined by direct observation at each study visit and by daily telephone/text message
reminders. Following completion of an antibiotic course, clearance of the challenge strain was
confirmed by microbiological culture of at least two stool samples obtained at least one week
apart, collected at least 3 weeks after completion of antibiotics.
Haematological, biochemical and microbiological assays after challenge
Routine haematological and biochemical monitoring was performed using blood samples col-
lected at challenge and at each visit thereafter. Blood (10mL) and stool samples were collected
for bacterial culture at each visit, while quantitative blood culture was performed using 10mL
of blood at the TD visit only. Cultures were performed by the local hospital accredited pathol-
ogy laboratories according to national standard operating procedures [21–24], and as previ-
ously described [19].
M01ZH09 and Typhoid Fever
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Participant clinical and safety data
In addition to regular clinical review, participants collected symptom data (solicited for head-
ache, feeling generally unwell, loss of appetite, abdominal pain, nausea/vomiting, myalgia,
arthralgia, cough, diarrhoea and constipation and any unsolicited symptoms) daily and twice-
daily self-recorded oral temperature readings using supplied written diary cards for 7 days after
vaccine and 28 days after challenge ingestion. Data from diary cards was confirmed and clari-
fied with the participant at each review.
Safety measures instituted included 24-hour contact with a study doctor, involvement of the
participant’s general practitioner, notification of the participant’s close-contacts of involve-
ment in the study, and provision of a 24-hour emergency contact who could be approached if
the participant could not be contacted. All screened individuals were consented for inclusion
onto The Over-volunteering Prevention System Database (TOPS)[25].
Statistical methods
Based on previous findings a challenge inoculum of 1-5x104 CFU was used to achieve an attack
rate of 60–75%. Assuming a similar attack rate in the placebo group using the same TD defini-
tions, then to demonstrate a protective effect of 83%, resulting in a reduction in attack rate to
10%, 21 participants would be needed per group. If the attack rate in the placebo group were to
fall to 50%, then 30 participants would be needed per group to demonstrate a protective effect
of vaccination of 80% with 90% power (1-β) at the 5% significance level (α). To include an
additional 10% dropout rate, target enrollment was 33 individuals per group.
Statistical comparisons were made between vaccine groups and placebo using the per proto-
col population, which included all participants completing the 14-day challenge period. The
study was not powered to compare the two active vaccine groups with each other and thus it
was pre-specified that these comparisons would not be performed.
The frequencies of TD in M01ZH09 (primary endpoint) or Ty21a recipients were compared
with placebo to calculate vaccine protective efficacy (VE, i.e. the percentage reduction in attack
rate in those vaccinated compared to the unvaccinated group) and presented along with 95%
confidence intervals. Sensitivity analyses compared VE under different definitions of typhoid
fever. Time to diagnosis (hours), time to development of fever (38°C, hours), and time to bac-
teraemia (point at which blood culture was collected, hours) were summarised using the
Kaplan-Meier method. A post hoc proportional hazards model assessed factors associated with
time to typhoid infection or time to bacteraemia, including vaccine receipt, baseline antibody
status and age, sex and travel to endemic regions.
Vaccine immunogenicity was assessed by log10-transformation of antibody levels measured
by ELISA and ASC counts (with 0 counts given a nominal value of 0.25). Comparisons between
groups were analysed using analysis of covariance (ANCOVA) models to adjust for pre-vacci-
nation titres. Comparisons of bacterial load and other non-normally distributed variables were
conducted using Mann-Whitney U tests. All reported p-values are two-tailed with statistical
significance at p<0.05. Analyses were performed using Stata version 13.0 (StataCorp, Texas,
USA) and SPSS Statistics version 22 (IBM, Portsmouth, UK).
Ethics statement
The UK National Research Ethics Service provided ethical approval for the trial (Oxfordshire
Research Ethics Committee A, 11/SC/0302), which was performed in accordance with the prin-
ciples of the ICH-Good Clinical Practice guidelines and amendments. All trial participants pro-
vided written informed consent in accordance with the Declaration of Helsinki (S1 Checklist).
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The study was registered at Clinicaltrials.gov (NCT01405521) and with the European Clini-
cal Trials database (EudraCT 2011-000381-35).
Results
Study participants
Ninety-nine participants were enrolled and randomised to one of three vaccine groups between
November 28, 2011, and June 27, 2012 (Fig 1, S1 Dataset). The demographic characteristics of
each group were similar (Table 1), with an overall median (range) participant age of 30.2 (19–
60) years, 64.6% male sex and 88.9% self-declared white British ethnicity. Of note, 29.6% of all
participants reported previous short periods of travel (<6months duration) to areas known to
be endemic for typhoid.
Of those randomised, 94/99 participants attended for vaccination. Compliance with fasting
requirements and vaccine schedules was high (98.5%). Four weeks after vaccination 92/94 par-
ticipants remained eligible and consented to challenge with S. Typhi. Challenge was performed
a median (range) of 27 (21–33) days after vaccine course completion and the median (range)
dose of S. Typhi bacteria ingested was 1.82 (1.46 to 2.66) x104 CFU (S1 Fig). Ninety-one partic-
ipants successfully completed the 2-week challenge period, and were included in the efficacy
and outcome assessments presented below.
Challenge outcomes and vaccine efficacy
Overall, 51/91 (56.0% [95% CI 45.2 to 66.4]) participants met the pre-specified criteria for
typhoid infection during the 2-week period post-challenge. Of these, 47/51 (92.2% [95%CI 81.1
to 97.8]) diagnoses were confirmed by positive blood culture. In the placebo group, 20/30
(66.7% [95%CI 39.1 to 75.5]) were diagnosed with typhoid producing an attack rate similar to
previous challenge studies (Table 2)[19]. After challenge, typhoid was diagnosed in 18/31
(58.1% [95%CI 39.1 to 75.5]) participants in the M01ZH09 and 13/30 (43.3% [95%CI 25.5 to
62.6]) in the Ty21a group, resulting in a calculated VE [95%CI] of 13% [-29% to 41%]) and
35% [-5% to 60%], respectively (Table 2).
Overall, a similar number of participants in each group were diagnosed by either clinical
(i.e. temperature38°C for12 hours) or blood culture criteria. This split in diagnosis type
was largely due to the time required for blood culture incubation and clinician notification; the
majority of participants (40/47, 85%) were bacteraemic at sampling points prior to the onset of
fever (38°C).
Estimates of VE were sensitive to changes in the definition of TD, ranging from 3% to 23%
for M01ZH09 and from 22% to 67% for Ty21a (Table 2). Of particular clinical interest, the
finding of fever (38°C) with a subsequent positive, confirmatory blood culture (an approxi-
mation for passive surveillance in field-testing conditions) resulted in VEs of 52% [-25% to
81%] and 80% [16% to 95%] for either single dose M01ZH09 or 3-doses of Ty21a, respectively.
By day 8 post-challenge, 8/31 (26%) M01ZH09 recipients and 12/30 (40%) Ty21a partici-
pants had reached the infection endpoint compared with 15/30 (50%) placebo recipients. The
Kaplan-Meier median [95%CI] time elapsed between challenge ingestion to development of
fever (38°C) or positive blood culture sampling was 265 [127 to 403] hours in M01ZH09
recipients or 172 [109 to 236] hours in placebo recipients, respectively (p = 0.249, log-rank; Fig
2).
Time to first positive blood culture in participants receiving M01ZH09 or Ty21a was
delayed compared with placebo (p = 0.042 and 0.047 respectively, log-rank; Fig 3A). Time to
onset of fever in participants was similar across groups (p = 0.1; Fig 3B).
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Severe typhoid infection was diagnosed in 11/91 (12%) study participants, with rates of 3/31
(10%) in M01ZH09, 4/30 (13%) in placebo and 1/30 (3%) in Ty21a recipients, respectively.
Most severe diagnoses (6/8) were defined by abnormalities in measured blood parameters only
(see Table 2).
Frequent and marked physiological changes and symptoms were found in the majority of
participants after challenge, particularly in those developing infection (Fig 4). Diary card
symptoms in blinded participants showed that participants receiving M01ZH09 had fewer,
milder symptoms compared to placebo (Fig 5, S1 Table). There were no clear differences in
the physiological parameters of participants diagnosed with infection among the different vac-
cine groups (Figs 6 and 7).
Microbiological outcomes
Over 1000 blood culture samples were collected from participants after challenge; due to the
later clinical presentation, M01ZH09 participants tended to have a greater number of samples
obtained than those in either of the other two groups (Table 3). The average number of positive
blood cultures collected from each typhoid-diagnosed participant was similar across groups
(2.25, 2.70 and 2.63 for those in M01ZH09, placebo and Ty21a groups, respectively). Of note,
the median [IQR] duration of blood culture positivity (measured from time of first positive to
last positive sampling) was similar between the M01ZH09 and placebo groups (28.7 [0 to 41.5]
and 27.7 [21.4 to 31.3] hours, respectively) but longer in Ty21a vaccine recipients (46.3 [28.4 to
53.3] hours).
The quantitative S. Typhi load (available for 41/51 diagnosed participants) at diagnosis
(prior to antibiotic initiation) was significantly lower in the blood of M01ZH09 and Ty21a
recipients compared with placebo (median [IQR] bacterial load CFU/mL, M01ZH09: 0.13
Fig 1. Study profile.During the screening process, participant exclusions were made either during initial telephone screening or at/after the study
centre screening visit. ‘Other’ reasons for exclusions were: contact with young children (3), contact with vulnerable individuals (9), food-related
occupation (5), previously resident in typhoid-endemic area for >6 months (15), unable to contact (6) & unknown (8).
doi:10.1371/journal.pntd.0004926.g001
Table 1. Participant characteristics by enrolled vaccine group.
Vaccine group
M01ZH09 Placebo Ty21a
Number 33 33 33
Male sex, number (%) 22 (66.7) 19 (57.6) 23 (69.7)
Age years, median (IQR) 24 (21–43) 23 (21–39) 25 (22–31)
White British ethnicity, number (%) 29 (87.9) 31 (93.9) 28 (84.8)
Employment status, %
Employed 31.3 45.5 48.4
Self-employed 6.3 3 6.5
Unemployed 12.5 6.1 0
Retired 6.3 0 0
Student 43.8 45.5 45.2
Alcohol consumption (any), % 81.8 90.9 97
Tobacco smoker (any), % 37.5 36.4 29.1
Other drug use (any), % 6.5 3 9.1
Previous travel to endemic area (<6 months duration),*% 31.2 24.2 33.3
* Note, previous travel to a typhoid endemic area >6months in duration was an exclusion criterion.
doi:10.1371/journal.pntd.0004926.t001
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[0.05–0.80], placebo: 1.30 [0.30–5.40]; p = 0.012; Ty21a: 0.05 [0.05–0.88]; p = 0.011, Mann-
Whitney U test; Fig 8).
Early shedding of S. Typhi in participant stool samples (within the first 72 hours after chal-
lenge) was frequent (44/91, 49% participants) and similar between vaccine groups (M01ZH09
55%, placebo 49%, Ty21a 47% of participants; Table 4). Identification of early shedding was
Table 2. Summary of vaccine efficacy endpoints and severity measures reached during the 14-day challenge period.
Attack rate, n (%) Vaccine efﬁcacy, %
[95% CI]
Adjusted Vaccine
efﬁcacy, % [95% CI]
M01ZH09 Placebo Ty21a M01ZH09 Ty21a M01ZH09 Ty21a
(n = 31) (n = 30) (n = 30)
PRIMARY OUTCOME—TYPHOID DIAGNOSIS
ALL reaching clinical or microbiological diagnosis deﬁnition 18 (58) 20 (67) 13 (43) 13 [-29 to
41]
35 [-5 to
60]
19 [-17 to
43]
31 [-8 to
55]
Clinical deﬁnition A 10 9 4 - -
Microbiological deﬁnition B 8 11 9 - -
SEVERE INFECTION
ALL reaching severe infection 3 (10) 4 (13) 1 (3)
Oral temperature 40.0°C 0 1 1
Systolic blood pressure85mmHg 0 0 0
Signiﬁcant confusion or lethargy 0 0 0
Gastrointestinal bleeding or suspected/conﬁrmed perforation 0 0 0
Grade 4 laboratory abnormality 3 C 3 D 0
Sensitivity Analyses of the primary outcome–varying deﬁnition
of typhoid diagnosis
Typhoid symptoms: Typhoid triad (any fever, headache plus
abdominal pain)
11 (31) 10 (30) 8 (30)
Fever threshold (any duration)
37.0°C 29 (94) 27 (90) 21 (70) -4 [-21 to
11]
22 [-1 to
40]
-6 [-33 to
16]
22 [-4 to
42]
37.5°C 19 (61) 21 (70) 12 (40) 12 [-26 to
39]
43 [6 to 65] 21 [-12 to
44]
40 [5 to 63]
38.0°C 16 (52) 18 (60) 9 (30) 14 [-35 to
45]
50 [7 to 73] 19 [-27 to
48]
48 [4 to 72]
38.5°C 13 (42) 13 (43) 7 (23) 3 [-73 to 46] 46 [-16 to
75]
7 [-69 to 49] 44 [-21 to
74]
39.0°C 9 (29) 9 (30) 3 (10) 3 [-110 to
55]
67 [-11 to
90]
10 [-99 to
59]
66 [-14 to
90]
Microbiological
Any S. Typhi bacteraemia 16 (52) 20 (67) 11 (37) 23 [-18 to
49]
45 [6 to 68] 28 [-7 to 52] 41 [2 to 64]
Bacteraemia or stool culture positive 21 (68) 26 (87) 16 (53) 22 [-3 to 41] 38 [12 to
57]
21 [-4 to 40] 29 [-2 to
50]
A Clinical endpoint: oral temperature38°C sustained for12 hours or more after Day 5 of challenge.
B Microbiological endpoint: blood culture positive for S. Typhi taken after Day 7 of challenge, or, a blood culture positive for S. Typhi plus objective symptoms
of typhoid infection taken after Day 5 of challenge.
C Grade 4 laboratory abnormalities M01ZH09 group: 2 hyperkalaemia (>5.6mEq/L), 1 Hypokalaemia (<3/1mEq/L).
D Grade 4 laboratory abnormalities Placebo group: 1 hyperkalaemia (>5.6mEq/L), 1 hypokalaemia (<3/1mEq/L), 1 elevated liver transaminases (>10x upper
limit of normal).
Adjusted vaccine efﬁcacy estimates are adjusted for baseline Vi titre.
doi:10.1371/journal.pntd.0004926.t002
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significantly associated with subsequent diagnosis of typhoid infection (relative risk [95% CI]
1.71 [1.15 to 2.53], p = 0.005, Chi-square test). From 72 hours after challenge onwards, S.
Typhi was cultured from 92/790 (12%) stool samples collected from 41/91 (45%) participants.
Overall, no differences in numbers of participants shedding S. Typhi were found in those diag-
nosed compared with participants who did not develop evidence of infection, either after day 4
or at any time point overall (p = 0.089 and p = 0.370 respectively, Chi-square test).
Antibiotic initiation rapidly terminated stool shedding, with no positive stool cultures being
obtained after the first dose of treatment had been taken. No evidence of convalescent or long-
term carriage of S. Typhi was found in any of the two follow-up stool cultures obtained.
Vaccine safety and immunogenicity
Both active vaccines and placebo were well tolerated and no Serious Adverse Events were iden-
tified related to vaccine receipt. Participants from each group reported a similar number and
severity of symptoms during the 7 days after vaccine receipt (Fig 9 and S1 Table).
Pre-vaccination (day -28) anti-LPS, -H and -Vi ASC levels measured by ELISpot and anti-
body titres measured by ELISA were similar between groups (S2 Table and S3 Table). One
week after a single dose of M01ZH09 or three doses of Ty21a, most participants showed a sig-
nificant increase in anti-LPS and anti-H ASC isotype assays compared with placebo (Fig 10A
and 10B, Table 5). Corresponding significant increases were seen in all anti-LPS and anti-H
Fig 2. Cumulative incidence of typhoid infection after S. Typhi challenge at Time = 0. Time to infection,
measured from challenge agent ingestion to development of first fever38°C or first positive blood culture
sampling. Non-diagnosed participants censored at 348 hours (dashed line). P value from log-rank test
comparing all three groups.
doi:10.1371/journal.pntd.0004926.g002
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antibody isotypes between day -28 and day 0 (prior to challenge ingestion) in response to
M01ZH09 vaccine when compared with placebo (Fig 10C and 10D, Table 6). In contrast, vac-
cination with Ty21a resulted in a borderline significant increases in anti-LPS IgG only
(p = 0.047, ANCOVA).
No significant increases in anti-Vi IgG antibody levels were found in response to vaccina-
tion. Of note, a range of anti-Vi IgG antibody titres was found at baseline. These included 6/32
(19%), 12/30 (40%) and 8/29 (28%) participants in the M01ZH09, placebo and Ty21a vaccine
groups respectively, with levels detectable above the lower detection limit (LLD, 7.4EU/mL)
and the 75% percentile measurement found in a UK adult blood donor population sample
(n = 81)[19].
Despite finding robust overall humoral anti-LPS and anti-H responses to vaccination, these
responses failed to confer protection against challenge (Fig 11A and 11B). While anti-Vi IgG
antibody titres were unaffected by the vaccines used in this study, baseline titres were signifi-
cantly higher in those subsequently found to be protected after challenge (Fig 11C). In an
exploratory proportional hazards analysis, baseline parameters were assessed for their impact
on developing typhoid during the 2-week challenge follow-up period. Anti-Vi antibody titre
prior to vaccination was the only variable found to be predictive of TD. Challenge dose, fold
increase in anti-LPS or anti-H antibody titres due to vaccination, sex and prior travel to
endemic regions were not significant. When baseline anti-Vi antibody levels were accounted
for in the model, the hazard rate of TD in the M01ZH09 group was approximately half that of
the placebo group (0.513, p = 0.048) and, similarly, time to bacteraemia rates were 60% lower
in both active vaccine groups compared with placebo (Table 7).
Discussion
For the first time in over 40 years we have demonstrated the utility of a human challenge study
in the assessment of a new typhoid vaccine candidate, M01ZH09. In phase I and IIa studies
performed to-date, in low and high transmission settings and in both adults and children, a sin-
gle dose of M01ZH09 has proven to be well tolerated and highly immunogenic [10–13]. In this
study, we found that neither a single dose M01ZH09 nor three doses of Ty21a given 28 days
prior to challenge resulted in significant overall protection. Both vaccines caused a significant
reduction in the microbiological burden of infection and alteration of the clinical disease pro-
files, however, when compared with those participants receiving placebo only. With adjust-
ment for baseline anti-Vi titre, M01ZH09 vaccine receipt resulted in significant protection
against developing typhoid fever during the two-week period after challenge.
We successfully demonstrated the reproducibility of this model for vaccine assessment by
recreating the attack rate of 67% in placebo recipients, identical to that described in our prelim-
inary dose-escalation study [19]. The selected challenge dose (and anticipated attack rate) was
chosen to avoid exposing excessive numbers of participants to a potentially infectious pathogen
while also attempting to reduce the risk of overwhelming potentially protective vaccine-
induced responses, as has been observed in some of the historical studies performed [26].
While we were able to document many of the features of clinical typhoid fever in our
Fig 3. Cumulative incidence of bacteraemia or fever after S. Typhi challenge at Time = 0. (A) Time to
bacteraemia, measured from challenge agent ingestion to time of first positive blood culture sampling. Non-
bacteraemic participants censored at time of diagnosis or at 348 hours (dashed line). P value from log-rank
test comparing all three groups and comparing M01ZH09 and Ty21a to placebo, respectively. (B) Time to
fever, measured from challenge agent ingestion to first recording of fever (oral temperature38°C). Afebrile
participants censored at time of diagnosis or at 336 hours (dashed line). P value from log-rank test comparing
all three groups.
doi:10.1371/journal.pntd.0004926.g003
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volunteers at this dose, this high attack rate in placebo recipients means that our model is likely
to be a more stringent test of VE than the historical Maryland model. In these studies, challenge
with 105 CFU S. Typhi Quailes strain 5–9 weeks after vaccination with 5–8 doses of Ty21a
resulted in high rates of anti-LPS antibody seroconversion and 87% protective efficacy, albeit
without the constraints of a two-week follow-up period [16].
To provide some measure of the ability of our challenge model to evaluate VE, we incorpo-
rated an open label Ty21a arm using the standard European 3-dose schedule. Despite resulting
in expected levels of immunogenicity [27], we found that Ty21a vaccination resulted in a pro-
tective efficacy of only 35% after challenge, a point estimate that did not reach significance.
Reasons for lower efficacy compared with that found in the historic Maryland studies might
include different dosing schedules and vaccine formulations used, the background immunity
of study participants, challenge doses and the methods used and the availability of automated
blood culture technology. It is interesting to note however, that a 35% VE corresponds to that
shown for the 3-dose schedule of Ty21a at Year 1 in a recent meta-analysis including 20,543
participants [6]. Likewise, with a similar definition for TD (fever with subsequent microbiolog-
ical confirmation) as was used in the original vaccine/challenge efficacy study by Gilman et al,
Ty21a VE reached 80% [95%CI, 16 to 95] in this study compared to 87% [95% CI, 47 to 96]
[16].
Lower Ty21a efficacy is also likely to reflect the higher challenge dose (and thus attack rates)
used in our study. Of note, the corresponding attack rate in the Maryland Ty21a studies was
53% after challenge with 105 CFU in non-vaccinated volunteers [16]. During the field trials of
Ty21a, VE was lowest in areas with higher infection rates and therefore probably higher expo-
sure doses. In Indonesia, where rates of infection were 1,206/100,000 for example, VE ranged
from 52.7% [95%CI. 23.9 to 58.6] in 3–19 year olds given three doses of liquid Ty21a to 23.6%
[95%CI, -78.8 to 67.3] in 20–44 year olds given 3 doses of enteric-coated Ty21a during 30
months of follow-up [28]. Reasons given for this lower efficacy in the older age group included
a lower number of cases in the placebo arm, possible variation in circulating S. Typhi strain
types or vaccine production. It is interesting to note both that the same enteric-coated formula-
tion was used in our study, and the relatively close phylogenetic relatedness of the Quailes
strain to more recently found Indonesian strains [19].
In keeping with the previous studies, we found M01ZH09 to be highly immunogenic and
well tolerated when given as a single oral dose. In addition to anti-LPS responses, significant
increases in anti-H ASC and antibody titres were also seen in M01ZH09 recipients, in contrast
to those vaccinated with Ty21a. Of note, a single dose of M01ZH09 contained approximately
twice as many CFU than 3-doses of Ty21a (1x1010 versus 6x109 CFU) although both vaccine
formulations would also contain non-viable bacteria. Despite the immune responses seen, and
against the expectation that high LPS antibody levels might correlate with protection against
Salmonella infection [14, 15, 26], vaccination failed to confer significant protection against
typhoid infection after challenge. Other beneficial effects of M01ZH09 vaccination were seen
however, suggesting that active vaccine-mediated mechanisms were in effect. These included a
noticeable delay in infection onset (effectively extending the clinical incubation period) charac-
terised as a delay in the appearance of fever and symptoms. It is noteworthy that delay in onset
of infection is used in many vaccine evaluation challenge models as evidence of VE [8]. There
was also a measurable reduction in the microbiological burden of infection, both in time to
Fig 4. Changes in physiological signs in those participants developing typhoid by time after
diagnosis according to vaccine group allocation. (A) Temperature, (B) Heart rate and (C) Systolic blood
pressure. Mean change from baseline and 95% confidence interval. Dashed black vertical line marks point of
typhoid diagnosis; grey horizontal bar indicates all participant mean (95%CI) values pre-vaccination.
doi:10.1371/journal.pntd.0004926.g004
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Fig 5. Proportion of participants reporting each solicited symptom during 14 days after challenge
according to vaccine group allocation. (A) Placebo, (B) M01ZH09, and (C) Ty21a vaccine recipient groups.
Maximum severity score per participant for each symptom was used and graded according to criteria detailed in the
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bacteraemia, the level of bacteraemia at TD and some reduction in stool shedding in the few
days preceding TD. While the precise immune mechanisms responsible for protection against
typhoid infection are still under investigation, these data confirm that, at least in typhoid-naïve
individuals, anti-LPS and anti-H responses may moderate the onset or severity of infection
symptoms, but are not sufficient alone to prevent invasion and systemic dissemination.
Generation of anti-LPS antibodies is frequently used as an indicator by which to select
potential oral vaccine candidates in addition to being the focus of several Salmonella-based vac-
cine programmes. Support for the protective role of anti-LPS responses comes from both field
trials, in which a correlation has been found between rates of anti-LPS seroconversion and sub-
sequent risk of typhoid infection [14], and mouse/S. Typhimurium models in which monoclo-
nal antibodies confer protection against homologous challenge [29]. A central argument to
using live attenuated vaccines in endemic settings is that protective immune responses may be
boosted by background exposure to S. Typhi in food or water supplies or due to persistence of
antigen in reticuloendothelial niches. This is likely responsible for the finding in field trials that
VE often increases over time. The two consequences for our study relate to the very low levels
study protocol: fever thresholds are Grade 1: 38.0–38.4°C; Grade 2: 38.5–38.9°C; Grade 3: 39.0–40.0°C; Grade 4:
>40.0°C.
doi:10.1371/journal.pntd.0004926.g005
Fig 6. Groupmean changes (95% confidence intervals) in haematological blood parameters compared to pre-challenge measurements
according to vaccine allocation and challenge outcome. (A) Haemoglobin, (B) platelets, (C) total white cell count, (D) neutrophils, (E) lymphocytes, and
(F) eosinophils. TD, typhoid diagnosis; nTD, non-typhoid diagnosis.
doi:10.1371/journal.pntd.0004926.g006
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Fig 7. Groupmean changes (95% confidence intervals) in biochemistry blood parameters compared to individual baseline measurements
according to vaccine allocation and challenge outcome. (A) Sodium, (B) potassium, (C) urea, (D) creatinine, (E) Albumin, (F) amylase, (G) alkaline
phosphatase, (H) alanine aminotransferase, (I) bilirubin, and (J) C-reactive protein. TD, typhoid diagnosis; nTD, non-typhoid diagnosis.
doi:10.1371/journal.pntd.0004926.g007
Table 3. Summary of microbiological results obtained over the entire study period (including stool clearance samples).
Vaccine group, n (%)
M01ZH09 Placebo Ty21a ALL
Blood cultures
S. Typhi 36 (9.7) 54 (15.6) 29 (8.7) 119 (11.3)
Others (i.e. contaminants)
Coagulase negative Staphylococci 3 6 6 15 (1.4)
Micrococcus sp. 0 1 0 1
Diphtheroids 0 0 1 1
Negative 331 285 295 911 (86.8)
Missing sample 0 0 1 1
Total sent 372 346 332 1050
Stool cultures
S. Typhi 47 (11.5) 53 (14.1) 49 (11.9) 149 (12.5)
Negative 362 321 361 1044
Missing sample 1 1 1 3
Total sent 410 375 411 1196
doi:10.1371/journal.pntd.0004926.t003
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of background LPS exposure, possibly resulting in suboptimal vaccine responses and thus less
protection to challenge, and the short window between vaccination and challenge. It is worth
noting that infants and young children are less likely to have experienced this background
exposure and therefore multiple vaccine doses may be more efficacious.
Post-hoc multivariate analyses to explore factors contributing to the development of
typhoid after challenge revealed the apparent protective contribution of vaccination when
adjusted for baseline anti-Vi IgG antibody titre. Participants were carefully selected to be both
typhoid and typhoid-vaccine naïve, by taking self-reported histories and confirming individu-
als’ vaccine and medical histories with their general practitioners. The finding that 29% of par-
ticipants had some measurable Vi antibody detectable (albeit at low levels) at baseline was
therefore unexpected. Reasons for this may include colonisation/exposure to cross-reactive or
homologous antigens (Citrobacter freundii 5396/38) or that those with very short travel histo-
ries may have been exposed, albeit briefly and sub-clinically to S. Typhi whilst abroad. Notably
there was no correlation found between overseas travel and detectable anti-Vi IgG. If con-
firmed in future planned studies, evidence of the protection afforded by even low levels of anti-
Vi IgG supports current Vi polysaccharide vaccine recommendations by the World Health
Organisation and prevention strategies in travellers and high-risk populations in endemic
regions [7], and for the development of newer more immunogenic Vi-conjugate vaccines.
Fig 8. Blood quantification of Salmonella Typhi bacteria present at point of typhoid diagnosis by
vaccine group. 10mL peripheral blood was collected at typhoid diagnosis (prior to antibiotic treatment) into
an Isolator 10 tube (Wampole Laboratories). Lysis centrifugation was performed (30min x 3000G without
brake) after which the deposit was plated to XLD and incubated aerobically at 37°C for 24 hours. After
incubation, colony counts and slide agglutination tests were performed. P values calculated using Mann
Whitney U test. Median [IQR] bacterial loads in CFU/mL were: M01ZH09 (n = 14): 0.13 [0.05–0.80]; Placebo
(n = 15): 1.30 [0.30–5.40]; Ty21a (n = 12): 0.05 [0.05–0.99]. Lower limit of detection, 0.1 CFU/mL; zero values
were substituted with LOD/2, i.e. 0.05 CFU/mL.
doi:10.1371/journal.pntd.0004926.g008
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Alternatively, low-level anti-Vi responses may be a marker for other cross protective
immune responses. Additional host mucosal and adaptive immune responses are likely to play
a major role in the protection afforded against infection by live-attenuated vaccine strains.
These include secretory IgA, classical and non-classical (HLA E-restricted) CD8+ cytotoxic T
cells [30], mucosal associated invariant T (MAIT) cell responses [31], regulatory T cell function
activation [32], and functional properties of monocyte and dendritic cells [33], and, as yet
incompletely characterised alterations in the gut microbiome [34]. Maturation of several of
these non-humoral responses may take longer than the 28-day period allowed between vacci-
nation and challenge in this study [30]. Additionally, thus far we have only explored the major
surface antigenic determinants (LPS, Vi and flagellin). Additional serum and secreted antibody
responses (to, for example, outer membrane proteins or GroEL) are also likely to play a role in
protection against infection. Likewise, functional antibody activity and antibody avidity may be
important in prevention of disease [15, 35].
To provide a uniform repeatable model of typhoid challenge, non-immune, typhoid-naïve
adults were specifically selected. While these findings may therefore not be directly extrapo-
lated to endemic field settings, they are likely to be relevant to travellers venturing to those
regions. The VE findings are therefore also likely to be an underestimate of efficacy in an
endemic setting, due to reasons of background exposure and antigen durability.
A major advantage of performing vaccine evaluation in a closed human challenge study, is
recognition of subclinical phenotypes of disease. While this allows a more accurate estimation
of vaccine effect, it also makes calculation of VE more susceptible to the disease endpoint defi-
nitions used. Our study incorporated demonstrable bacteraemia in the primary endpoint defi-
nition; previous challenge studies and field efficacy studies predated the development of more
sensitive automated culture techniques and used a passive surveillance system to detect illness
in the community participants. We therefore likely ‘overcalled’ those with infection, resulting
in an apparently higher attack rate in our highly-controlled, intensively sampled participants
Table 4. Summary of stool shedding by participants between Day 0 (including pre-challenge) until completion of challenge, according to vaccine
group allocation, challenge outcome and phase of shedding.
Group Challenge outcome Time point Any time point
Day 0 to Day 3 Day 4 onward$ Day 4 to TD TD onward
M01ZH09 nTD 5/13 (38) 4/13 (31) 8/13 (62)
TD 12/18 (67) 7/18 (39) 7/18 0/16 12/18 (67)
ALL 17/31 (55) 11/31 (35) 20/31 (65)
Placebo nTD 3/10 (30) 6/10 (60) 7/10 (70)
TD 10/19 (53) 10/20 (50) 10/20 0/20 12/20 (60)
ALL 13/29* (49) 16/30 (53) 19/30 (63)
Ty21a nTD 5/17 (29) 4/17 (24) 8/17 (47)
TD 9/13 (69) 10/13 (77) 10/13 0/13 10/13 (77)
ALL 14/30 (47) 14/30 (47) 18/30 (60)
ALL nTD 13/40 (33) 14/40 (35) 23/40 (58)
TD 31/50 (62) 27/51 (53) 34/51 (67)
ALL 44/90 (49) 41/91 (45) 57/91 (63)
nTD, Typhoid not diagnosed; TD, typhoid diagnosis.
*Note, one placebo recipient produced no stool samples before Day 4.
$ Day 4 to Day 18 (day of last sample submission from individual still having challenge follow-up visits, i.e. last TD+96 hours visit).
doi:10.1371/journal.pntd.0004926.t004
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than may have been found in these historical studies and had the vaccine been assessed in
under field conditions.
In this unique study, we demonstrate the safety and utility of an ambulant outpatient
human challenge study in evaluating the efficacy of a new typhoid vaccine candidate. While
Fig 9. Proportion of participants reporting each solicited symptom during the 7-days after receipt of (first) vaccine dose. (A)
Placebo, (B) M01ZH09, and (C) Ty21a vaccine recipient groups. Maximum severity score per participant for each symptom was used;
grade 1: symptom reported but no interference with daily activity; grade 2: some interference with normal daily activities; grade 3:
significant symptoms preventing normal daily activity; grade 4: potentially life-threatening (see S1 Protocol).
doi:10.1371/journal.pntd.0004926.g009
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M01ZH09 failed to demonstrate significant protection in the per protocol analysis, post hoc
analyses provide the intriguing possibility that this single dose vaccine may provide up to 50%
protection in this stringent challenge model. That low level anti-Vi antibody appears to be pro-
tective supports current efforts to develop a conjugate-Vi vaccine suitable for use in younger
children, however the emergence of Vi-negative S. Typhi strains and S. Paratyphi as under-
scores the importance of pursuing alternative strategies, including the development of live-
attenuated vaccines. If a single dose of M01ZH09 reduces the risk of infection after challenge
by half and has an impact on shedding, and therefore potentially transmission, oral vaccination
could be a readily delivered public health control strategy.
Fig 10. Immunoglobulin G ASC and antibody responses to S. Typhi LPS and flagellin before (Day -28) and after vaccination (either Day -21 or
Day 0 for ASC and ELISA assays, respectively). (A) LPS and (B) flagellin specific IgG antibody secreting cell responses, respectively, measured
pre-vaccination (Day -28) and 7 days later (Day -21). (C) Anti-LPS and (D) anti-flagellin antibody titres, respectively, measured pre-vaccination (Day
-28) and 28 days later (Day 0, i.e. prior to S. Typhi challenge). Data are grouped according to vaccine allocation.
doi:10.1371/journal.pntd.0004926.g010
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Table 5. Analysis of covariance comparisons for increase in ASC titres against LPS, flagellin (H) and Vi between prevaccination (Day -28) and Day
-21, between each active vaccine group (1. M01ZH09 and 2. Ty21a) and placebo. Analyses were performed with the dependent variable log(change
from baseline) with adjustment for log(pre-vaccination) values. GMR, geometric mean ratio compared to placebo.
Variable Vaccine group GMR 95% CI P value
(vaccine/placebo)
LPS IgG M01ZH09 11.2 4.7 to 26.2 < .0001
Ty21a 1.8 0.7 to 4.3 0.189
LPS IgM M01ZH09 74.9 37.0 to 151.6 < .0001
Ty21a 6.2 3.0 to 12.7 < .0001
LPS IgA M01ZH09 43.4 20.8 to 90.8 < .0001
Ty21a 5.6 2.6 to 11.8 < .0001
H IgG M01ZH09 35.9 16.4 to 78.3 < .0001
Ty21a 3.6 1.6 to 8.1 0.002
H IgM M01ZH09 119.5 63.1 to 226.4 < .0001
Ty21a 7.6 3.9 to 14.6 < .0001
H IgA M01ZH09 64.4 32.3 to 128.5 < .0001
Ty21a 8.0 3.9 to 16.2 < .0001
Vi IgG M01ZH09 0.6 0.3 to 1.2 0.1670
Ty21a 0.7 0.4 to 1.4 0.334
Vi IgM M01ZH09 2.3 1.1 to 4.7 0.031
Ty21a 1.0 0.5 to 2.2 0.925
Vi IgA M01ZH09 1.1 0.5 to 2.1 0.880
Ty21a 1.2 0.6 to 2.5 0.586
doi:10.1371/journal.pntd.0004926.t005
Table 6. Analysis of covariance comparisons for increase in antibody titres against LPS, flagellin (H) and Vi between pre-vaccination (Day -28) and
Day 0 (prior to challenge), between each active vaccine group (1. M01ZH09 and 2. Ty21a) and placebo. Analysis were performed with the dependent
variable log(change from baseline) with adjustment for log(pre-vaccination) values. GMR, geometric mean ratio compared to placebo.
Variable Vaccine Group GMR 95% CI P value
(vaccine/placebo)
LPS IgG M01ZH09 2.7 1.9 to 4.0 < .0001
Ty21a 1.5 1.0 to2.2 0.047
LPS IgM M01ZH09 1.6 1.4 to 2.0 < .0001
Ty21a 1.1 0.9 to 1.3 0.255
LPS IgA M01ZH09 1.8 1.4 to 2.2 < .0001
Ty21a 1.2 1.0 to 1.5 0.092
H IgG M01ZH09 2.7 1.9 to 3.6 < .0001
Ty21a 1.0 0.7 to 1.4 0.900
H IgM M01ZH09 26.7 14.0 to 51.2 < .0001
Ty21a 1.4 0.7 to 2.7 0.282
H IgA M01ZH09 2.7 2.0 to 3.5 < .0001
Ty21a 1.1 0.8 to 1.5 0.466
Vi IgG M01ZH09 1.0 0.9 to 1.2 0.790
Ty21a 1.0 0.8 to 1.1 0.593
doi:10.1371/journal.pntd.0004926.t006
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S1 Protocol. Understanding typhoid disease after vaccination: A single centre, randomised,
double-blind, placebo-controlled study to evaluate M01ZH09 in a healthy adult challenge
model, using Ty21a vaccine as a positive control.OVG2011/02
(PDF)
S1 Fig. Challenge doses dispensed to 92 participants according to batch (co-challenged par-
ticipants) and typhoid challenge outcome. TD, typhoid diagnosed, filled circles; nTD
Typhoid not diagnosed, clear circles. Challenge dose administered was measured by direct plat-
ing from the challenge suspension onto tryptone soya agar (Oxoid) prior to colony counting
after 24 hours incubation (37°C, 5%CO2). Challenge doses ranged from 1.46–2.66x10
4CFU S.
Fig 11. Pre-vaccination (Day -28) and pre-challenge (Day 0) IgG antibody titres according to outcome after challenge. (A) Anti-LPS IgG, (B)
anti-H IgG, and (C) anti-Vi IgG. Clear circles, non-typhoid diagnosed participants; black circles, typhoid diagnosed participants. Difference between
Day -28 and Day 0 anti-LPS and anti-H antibodies analysed by ANCOVA adjusted for vaccine group and baseline titre; P values for anti-Vi antibody
calculated byWilcoxon Rank Sum. Lower limit-of Vi-antibody detection, 7.4EU/mL.
doi:10.1371/journal.pntd.0004926.g011
Table 7. Hazard Ratios (each active vaccine group vs. placebo) and 95% confidence intervals from proportional hazards models adjusting for
baseline anti-Vi IgG antibody titres.
Predictor HR 95% CI p value
Time to typhoid diagnosis Ty21a 0.572 0.283 to 1.157 0.120
M01ZH09 0.513 0.264 to 0.994 0.048
Log10(anti-Vi)* 0.290 0.120 to 0.700 0.006
Time to bacteraemia Ty21a 0.428 0.204 to 0.901 0.026
M01ZH09 0.407 0.205 to 0.810 0.011
Log10(anti-Vi)* 0.272 0.106 to 0.695 0.007
* hazard ratio per 1 log10 increase in anti-Vi IgG titre
doi:10.1371/journal.pntd.0004926.t007
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Typhi Quailes strain; median dose given was 1.82x104 CFU denoted by dashed horizontal line.
Scheduling of participants to receive challenge occurred at their convenience but in batches so
far as possible, to enable logistic configuration of laboratory and clinical staffing. Batch size
ranged from 1–10 participants (median n = 4, IQR 2–5); all participants within a batch were
challenged on the same day and with the same challenge dose.
(PDF)
S1 Table. Frequency of solicited reports of adverse events during the first 7 days after vac-
cine administration and during the first 21 days after challenge, according to vaccine
group allocation. Severity is mean score. Symptoms in bold text represent the ‘classical triad’
of typhoid fever presentation: fever, headache and abdominal pain.
(PDF)
S2 Table. Plasma antibody-secreting cell responses to vaccination with M01ZH09, placebo
or Ty21a. Geometric mean concentration, GMC (95%CI). Lower limit-of-detection, 0.25 cells/
106PBMC. PBMC, peripheral blood mononuclear cells. GMC, measured in ASC/106 peripheral
blood mononuclear cells (PBMC).
(PDF)
S3 Table. Anti-LPS, anti-H, anti-Vi antibody responses to vaccination with M01ZH09, pla-
cebo or Ty21a. Geometric mean titre (95%CI). Lower limit-of-antibody detection, 7.4EU/mL.
(PDF)
Acknowledgments
We would like to thank the study participants and volunteers. We are grateful to the Health
Protection Agency (now Public Health England) Porton Down for challenge strain manufac-
ture to GMP standard. We also acknowledge the kind support of Professor Derrick Crook and
the work performed by the microbiology, haematology and clinical chemistry laboratories at
the Oxford University Hospitals NHS Trust, Dr Noel McCarthy and the Thames Valley Health
Protection Unit. In addition we gratefully acknowledge the support and advice provided by the
Data Safety and Monitoring Committee, the additional clinical and laboratory support pro-
vided by the Oxford Vaccine Group and Dr Raphael Simon at the University of Maryland
School of Medicine for supply of purified flagellin protein.
Author Contributions
Conceptualization: TCD CSWGDMML AJP.
Data curation: CJ AP KH RS MM BAVT.
Formal analysis: TCD LMYMV.
Funding acquisition: AJP.
Investigation: TCD CJ CJB CSW LZ AP KH RS CAG CAJ MM BAVT BA.
Methodology: TCD CJ CSW LZ KH BAVT TJ LMY AJP.
Project administration: TCD KH BAVT TJ BA AJP.
Resources: RAK ZH SL MBS GDMML AJP.
Supervision: SL MBS GD BAMML AJP.
Visualization: TCD CJB MV.
M01ZH09 and Typhoid Fever
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004926 August 17, 2016 25 / 27
Writing - original draft: TCD.
Writing - review & editing: TCD CJ CJB CSW KH CAG BAVT LMYMV ZH SL MBS BA
MML AJP.
References
1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality
from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Bur-
den of Disease Study 2010. Lancet. 2012; 380(9859):2095–128. Epub 2012/12/19. doi: 10.1016/
S0140-6736(12)61728-0 PMID: 23245604
2. Rahman MM, Gilmour S, Saito E, Sultana P, Shibuya K. Self-reported illness and household strategies
for coping with health-care payments in Bangladesh. Bulletin of the World Health Organization. 2013;
91(6):449–58. doi: 10.2471/BLT.12.115428 PMID: 24052682
3. Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD, et al. A study of
typhoid fever in five Asian countries: disease burden and implications for controls. Bulletin of the World
Health Organization. 2008; 86(4):260–8. PMID: 18438514
4. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bulletin of the World Health Organi-
zation. 2004; 82(5):346–53. Epub 2004/08/10. PMID: 15298225
5. World Health Organisation. Meeting of the Strategic Advisory Group of Experts on Immunization,
November 2010—summary, conclusions and recommendations. Weekly Epidemiological Record.
2011; 86(1–2):1–16.
6. Anwar E, Goldberg E, Fraser A, Acosta CJ, Paul M, Leibovici L. Vaccines for preventing typhoid fever.
The Cochrane database of systematic reviews. 2014; 1:Cd001261. Epub 2014/01/05. doi: 10.1002/
14651858.CD001261.pub3 PMID: 24385413
7. World Health Organisation. Typhoid vaccines: WHO position paper. Weekly Epidemiological Record.
2008; 6(83):49–60.
8. Darton TC, Blohmke CJ, Moorthy VS, Altmann DM, Hayden FG, Clutterbuck EA, et al. Design, recruit-
ment, and microbiological considerations in human challenge studies. The Lancet infectious diseases.
2015; 15(7):840–51. doi: 10.1016/S1473-3099(15)00068-7 PMID: 26026195
9. Hindle Z, Chatfield SN, Phillimore J, Bentley M, Johnson J, Cosgrove CA, et al. Characterization of Sal-
monella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III
secretion system (ssaV) mutations by immunization of healthy volunteers. Infection and immunity.
2002; 70(7):3457–67. Epub 2002/06/18. PMID: 12065485
10. Kirkpatrick BD, McKenzie R, O'Neill JP, Larsson CJ, Bourgeois AL, Shimko J, et al. Evaluation of Sal-
monella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella
pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine. 2006; 24(2):116–
23. Epub 2005/09/06. PMID: 16140433
11. Kirkpatrick BD, Tenney KM, Larsson CJ, O’Neill JP, Ventrone C, Bentley M, et al. The novel oral
typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. The
Journal of infectious diseases. 2005; 192(3):360–6. PMID: 15995948
12. Tran TH, Nguyen TD, Nguyen TT, Ninh TT, Tran NB, Nguyen VM, et al. A randomised trial evaluating
the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Viet-
namese children. PloS one. 2010; 5(7):e11778. Epub 2010/07/30. doi: 10.1371/journal.pone.0011778
PMID: 20668668
13. Lyon CE, Sadigh KS, Carmolli MP, Harro C, Sheldon E, Lindow JC, et al. In a randomized, double-
blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immuno-
genic at doses up to 1.7 x 10(10) colony-forming units. Vaccine. 2010; 28(20):3602–8. Epub 2010/03/
02. doi: 10.1016/j.vaccine.2010.02.017 PMID: 20188175
14. Levine MM, Ferreccio C, Black RE, Tacket CO, Germanier R. Progress in vaccines against typhoid
fever. Reviews of infectious diseases. 1989; 11 Suppl 3:S552–67. PMID: 2669099
15. Lindow JC, Fimlaid KA, Bunn JY, Kirkpatrick BD. Antibodies in action: role of human opsonins in killing
Salmonella enterica serovar Typhi. Infection and immunity. 2011; 79(8):3188–94. doi: 10.1128/IAI.
05081-11
16. Gilman RH, Hornick RB, WoodardWE, DuPont HL, Snyder MJ, Levine MM, et al. Evaluation of a UDP-
glucose-4-epimeraseless mutant of Salmonella Typhi as a liver oral vaccine. The Journal of infectious
diseases. 1977; 136(6):717–23. PMID: 925379
M01ZH09 and Typhoid Fever
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004926 August 17, 2016 26 / 27
17. Hornick RB, Greisman SE, Woodward TE, DuPont HL, Dawkins AT, Snyder MJ. Typhoid fever: patho-
genesis and immunologic control. 2. The New England journal of medicine. 1970; 283(14):739–46.
Epub 1970/10/01. PMID: 4916916
18. Levine MM, Tacket CO, Sztein MB. Host-Salmonella interaction: human trials. Microbes and infection /
Institut Pasteur. 2001; 3(14-15):1271–9. Epub 2002/01/05. doi: 10.1016/S1286-4579(01)01487-3
PMID: 11755415.
19. Waddington CS, Darton TC, Jones C, Haworth K, Peters A, John T, et al. An outpatient, ambulant-
design, controlled human infection model using escalating doses of Salmonella Typhi challenge deliv-
ered in sodium bicarbonate solution. Clinical infectious diseases : an official publication of the Infectious
Diseases Society of America. 2014; 58(9):1230–40. Epub 2014/02/13. doi: 10.1093/cid/ciu078 PMID:
24519873.
20. Electronic Medicines Compendium. Summary of Product Characteristics: Vivotif: Datapharm Comm-
nuications Ltd; 2013 [updated 01/04/2012; cited 2013 18 Jun 2013]. Available from: http://www.
medicines.org.uk/emc/medicine/26276/SPC/.
21. Bale JA, de Pinna EM, Threlfall E, Ward LR, Centre for Infections (Health Protection Agency). Kauff-
mann-White scheme - 2007 : salmonella identification : serotypes and antigen formulae. London: Cen-
tre for Infections, Health Protection Agency; 2007.
22. Health Protection Agency. Identification of Salmonella species: UK Standards for Microbiology Investi-
gations; 2011. Available from: http://www.hpa.org.uk/SMI/pdf.
23. Health Protection Agency. Investigation of faecal specimens for enteric pathogens: UK Standards for
Microbiology Investigations; 2013. Available from: http://ww.hpa.org.uk/SMI/pdf.
24. Health Protection Agency. Investigation of blood cultures (for organisms other thanMycobacterium
species): UK Standards for Microbiological Investigations; 2013. Available from: http://www.hpa.org.
uk/SMI/pdf.
25. UK Health Research Authority. The Over Volunteering Prevention System 2013 [updated 26 Mar
201330 Jan 2014]. Available from: http://www.tops.org.uk/site/cms/contentChapterView.asp?chapter=
1.
26. Waddington CS, Darton TC, WoodwardWE, Angus B, Levine MM, Pollard AJ. Advancing the manage-
ment and control of typhoid fever: A review of the historical role of human challenge studies. The Jour-
nal of infection. 2014; 68:405–18. Epub 2014/02/05. doi: 10.1016/j.jinf.2014.01.006 PMID: 24491597
27. Kantele A, Pakkanen SH, Karttunen R, Kantele JM. Head-to-head comparison of humoral immune
responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines—a randomized
trial. PloS one. 2013; 8(4):e60583. Epub 2013/04/18. doi: 10.1371/journal.pone.0060583 PMID:
23593253
28. Simanjuntak CH, Paleologo FP, Punjabi NH, Darmowigoto R, Soeprawoto, Totosudirjo H, et al. Oral
immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet. 1991; 338(8774):1055–9.
Epub 1991/10/26. PMID: 1681365
29. Colwell DE, Michalek SM, Briles DE, Jirillo E, McGhee JR. Monoclonal antibodies to Salmonella lipo-
polysaccharide: anti-O-polysaccharide antibodies protect C3Hmice against challenge with virulent Sal-
monella typhimurium. The Journal of Immunology. 1984; 133(2):950–7. PMID: 6203984
30. Salerno-Goncalves R, Wahid R, Sztein MB. Ex Vivo kinetics of early and long-termmultifunctional
human leukocyte antigen E-specific CD8+ cells in volunteers immunized with the Ty21a typhoid vac-
cine. Clinical and vaccine immunology: CVI. 2010; 17(9):1305–14. Epub 2010/07/28. doi: 10.1128/CVI.
00234-10 PMID: 20660136
31. Salerno-Goncalves R, Rezwan T, Sztein MB. B Cells Modulate Mucosal Associated Invariant T Cell
Immune Responses. Frontiers in Immunology. 2013; 4:511. doi: 10.3389/fimmu.2013.00511 PMID:
PMC3882667.
32. McArthur MA, Fresnay S, Magder LS, Darton TC, Jones C, Waddington CS, et al. Activation of Salmo-
nella Typhi-specific regulatory T cells in typhoid disease in a wild-type S. Typhi challenge model. PLoS
pathogens. 2015; 11(5):e1004914. doi: 10.1371/journal.ppat.1004914 PMID: 26001081
33. Toapanta FR, Bernal PJ, Fresnay S, Darton TC, Jones C, Waddington CS, et al. Oral Wild-Type Salmo-
nella Typhi Challenge Induces Activation of Circulating Monocytes and Dendritic Cells in Individuals
Who Develop Typhoid Disease. PLoS neglected tropical diseases. 2015; 9(6):e0003837. doi: 10.1371/
journal.pntd.0003837 PMID: 26065687
34. Sztein MB, Salerno-Goncalves R, McArthur MA. Complex adaptive immunity to enteric fevers in
humans: lessons learned and the path forward. Front Immunol. 2014; 5:516. doi: 10.3389/fimmu.2014.
00516 PMID: 25386175
35. Boyd MA, Tennant SM, Saague VA, Simon R, Muhsen K, Ramachandran G, et al. Serum bactericidal
assays to evaluate typhoidal and nontyphoidal Salmonella vaccines. Clinical and vaccine immunology:
CVI. 2014; 21(5):712–21. Epub 2014/03/14. doi: 10.1128/CVI.00115-14 PMID: 24623629
M01ZH09 and Typhoid Fever
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004926 August 17, 2016 27 / 27
